ProQuest Associates IV’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

ProQuest Associates IV’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-6,777	Closed	-$513K	–	5
2018 Q2	$513K	Hold	6,777	–	–	0.79%	5
2018 Q1	$357K	Hold	6,777	–	–	0.41%	5
2017 Q4	$362K	Hold	6,777	–	–	0.48%	5
2017 Q3	$404K	Sell	6,777 -5	-0.1%	-$302	0.4%	5
2017 Q2	$535K	Sell	6,782 -3,645,502	-100%	-$298M	0.68%	5
2017 Q1	$303M	Sell	3,652,284 -299,794	-8%	-$22.3M	91.1%	1
2016 Q4	$314M	Sell	3,952,078 -430,686	-10%	-$31.3M	88.77%	1
2016 Q3	$307M	Sell	4,382,764 -397,424	-8%	-$22M	84.52%	1
2016 Q2	$185M	Hold	4,780,188	–	–	75.43%	1
2016 Q1	$194M	Hold	4,780,188	–	–	75.2%	1
2015 Q4	$424M	Hold	4,780,188	–	–	81.8%	1
2015 Q3	$354M	Hold	4,780,188	–	–	83.76%	1
2015 Q2	$387M	Hold	4,780,188	–	–	79.39%	1
2015 Q1	$200M	Buy	4,780,188 +39,001	+0.8%	+$1.11M	65.32%	1
2014 Q4	$73.5M	Buy	+4,741,187	New	+$60.5M	37.25%	2

Other funds holding EGRX

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HEC

Hudson Executive Capital New York $50.9M AUM 22.11% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.47B AUM 86.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

JAM

JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

ProQuest Associates IV's EGRX Position: Q3 2018 in Review

ProQuest Associates IV sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q3 2018, closing a stake of 6,777 shares — an estimated $513K sold.

ProQuest Associates IV first reported a position in EGRX in Q4 2014 and held it in 15 quarters. The position peaked at $424M in Q4 2015. 189 funds tracked by Wall St. Rank hold EGRX as of Q3 2018.

ProQuest Associates IV reported no remaining Eagle Pharmaceuticals, Inc. position as of Q3 2018 after selling out during the quarter.
ProQuest Associates IV sold 6,777 Eagle Pharmaceuticals, Inc. shares in Q3 2018, an estimated $513K.
ProQuest Associates IV first reported a position in Eagle Pharmaceuticals, Inc. in Q4 2014 and held it in 15 quarters.
ProQuest Associates IV's Eagle Pharmaceuticals, Inc. position peaked at $424M in Q4 2015.
189 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q3 2018.

Based on ProQuest Associates IV's 13F filing for Q3 2018, filed 14 Nov 2018.